title: Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model.
abstract: To facilitate quantitation of cellular apoptotic responses to various antineoplastic agents, a laser-based technology, Optophoresis, has been developed to provide analysis of cells without any need for labeling or cell processing. Optophoresis is defined as the analysis of the motion of cells, where the motion is either induced or modified by a moving optical gradient field, which produces radiation pressure forces on the cells in an aqueous suspension. Quantitation of the induced motion provides a basis for distinguishing one population of cells from another. One Optophoretic technique, Fast Scan, measures the distribution of distances traversed by a population of cells when exposed to a fast-moving optical gradient. Fast Scan was validated using a cell-based model of chronic myeloid leukemia treated with Gleevec, a specific inhibitor of aberrant Bcr-Abl protein kinase. The Optophoretic measurements were quantitatively comparable to reference assays with regard to drug selectivity and potency and to target specificity, demonstrating the suitability of this technology for pharmaceutical and clinical applications.
authors.affiliation: Genoptix Inc., 3398 Carmel Mountain Road, San Diego, CA 92121, USA.
authors.forename: Anita H
authors.initials: AH
authors.lastname: Forster
authors.forename: Mark M
authors.initials: MM
authors.lastname: Wang
authors.forename: William F
authors.initials: WF
authors.lastname: Butler
authors.forename: Mirianas
authors.initials: M
authors.lastname: Chachisvilis
authors.forename: Thomas D Y
authors.initials: TD
authors.lastname: Chung
authors.forename: Sadik C
authors.initials: SC
authors.lastname: Esener
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Hall
authors.forename: Osman
authors.initials: O
authors.lastname: Kibar
authors.forename: Kristie
authors.initials: K
authors.lastname: Lykstad
authors.forename: Philippe J
authors.initials: PJ
authors.lastname: Marchand
authors.forename: Elinore M
authors.initials: EM
authors.lastname: Mercer
authors.forename: Luis M
authors.initials: LM
authors.lastname: Pestana
authors.forename: Sudipto
authors.initials: S
authors.lastname: Sur
authors.forename: Eugene
authors.initials: E
authors.lastname: Tu
authors.forename: Rong
authors.initials: R
authors.lastname: Yang
authors.forename: Haichuan
authors.initials: H
authors.lastname: Zhang
authors.forename: Ilona
authors.initials: I
authors.lastname: Kariv
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D001681:Biological Assay; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D005453:Fluorescence; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism* / Q000473:pathology; D008163:Luminescent Measurements; D008853:Microscopy / Q000295:instrumentation / Q000379:methods*; D010879:Piperazines / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D020169:Caspases